Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin.

Helmut Steinberg, Matt S. Anderson, Thomas Musliner, Mary E. Hanson, Samuel S. Engel

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The risk of death due to heart disease and stroke is up to four times higher in individuals with diabetes compared to individuals without diabetes. Most guidelines that address treatment of dyslipidemia in patients with diabetes consider diabetes a cardiovascular disease (CVD) "risk equivalent" and recommend intensive treatment of dyslipidemia for the purpose of CVD prevention. Statins (3-hydroxy 3-methylglutaryl coenzyme A reductase [HMG-CoA reductase] inhibitors) are first-line agents in achieving lipid goals as an adjunct to diet and exercise and should be used in most patients. In addition to lipid management and blood pressure control, glycemic control is a basic component in the management of diabetes. Glycemic control is achieved by combining diabetes self-management education, diet and exercise, and, where required, antihyperglycemic agents (OHAs). Persistence and adherence to therapy are critical in achieving recommended treatment goals. However, overall compliance with concomitantly prescribed OHAs and statins is low in patients with type 2 diabetes. Fixed-dose combination (FDC) therapies have been shown to improve adherence by reducing pill burden, the complexity of treatment regimen, and, potentially, cost. Based on the available evidence regarding the pharmacokinetics and the efficacy and safety profiles of each component drug, the sitagliptin/simvastatin FDC may provide a rational and well-tolerated approach to achieving better adherence to multiple-drug therapy and improved lipid lowering and glycemic control, with consequent reduction in cardiovascular risk, diabetic microvascular disease, and mortality in diabetic patients for whom treatment with both compounds is appropriate.

Original languageEnglish (US)
Pages (from-to)273-282
Number of pages10
JournalVascular Health and Risk Management
Volume9
StatePublished - Dec 1 2013
Externally publishedYes

Fingerprint

Simvastatin
Dyslipidemias
Hyperglycemia
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipids
Therapeutics
Cardiovascular Diseases
Exercise
Diet
Self Care
Sitagliptin Phosphate
Hypoglycemic Agents
Type 2 Diabetes Mellitus
Heart Diseases
Oxidoreductases
Pharmacokinetics
Stroke
Guidelines
Blood Pressure
Safety

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Hematology
  • Public Health, Environmental and Occupational Health
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. / Steinberg, Helmut; Anderson, Matt S.; Musliner, Thomas; Hanson, Mary E.; Engel, Samuel S.

In: Vascular Health and Risk Management, Vol. 9, 01.12.2013, p. 273-282.

Research output: Contribution to journalReview article

Steinberg, Helmut ; Anderson, Matt S. ; Musliner, Thomas ; Hanson, Mary E. ; Engel, Samuel S. / Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. In: Vascular Health and Risk Management. 2013 ; Vol. 9. pp. 273-282.
@article{f3e2678ce8a446ea8a3d36521de50739,
title = "Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin.",
abstract = "The risk of death due to heart disease and stroke is up to four times higher in individuals with diabetes compared to individuals without diabetes. Most guidelines that address treatment of dyslipidemia in patients with diabetes consider diabetes a cardiovascular disease (CVD) {"}risk equivalent{"} and recommend intensive treatment of dyslipidemia for the purpose of CVD prevention. Statins (3-hydroxy 3-methylglutaryl coenzyme A reductase [HMG-CoA reductase] inhibitors) are first-line agents in achieving lipid goals as an adjunct to diet and exercise and should be used in most patients. In addition to lipid management and blood pressure control, glycemic control is a basic component in the management of diabetes. Glycemic control is achieved by combining diabetes self-management education, diet and exercise, and, where required, antihyperglycemic agents (OHAs). Persistence and adherence to therapy are critical in achieving recommended treatment goals. However, overall compliance with concomitantly prescribed OHAs and statins is low in patients with type 2 diabetes. Fixed-dose combination (FDC) therapies have been shown to improve adherence by reducing pill burden, the complexity of treatment regimen, and, potentially, cost. Based on the available evidence regarding the pharmacokinetics and the efficacy and safety profiles of each component drug, the sitagliptin/simvastatin FDC may provide a rational and well-tolerated approach to achieving better adherence to multiple-drug therapy and improved lipid lowering and glycemic control, with consequent reduction in cardiovascular risk, diabetic microvascular disease, and mortality in diabetic patients for whom treatment with both compounds is appropriate.",
author = "Helmut Steinberg and Anderson, {Matt S.} and Thomas Musliner and Hanson, {Mary E.} and Engel, {Samuel S.}",
year = "2013",
month = "12",
day = "1",
language = "English (US)",
volume = "9",
pages = "273--282",
journal = "Vascular Health and Risk Management",
issn = "1176-6344",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin.

AU - Steinberg, Helmut

AU - Anderson, Matt S.

AU - Musliner, Thomas

AU - Hanson, Mary E.

AU - Engel, Samuel S.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - The risk of death due to heart disease and stroke is up to four times higher in individuals with diabetes compared to individuals without diabetes. Most guidelines that address treatment of dyslipidemia in patients with diabetes consider diabetes a cardiovascular disease (CVD) "risk equivalent" and recommend intensive treatment of dyslipidemia for the purpose of CVD prevention. Statins (3-hydroxy 3-methylglutaryl coenzyme A reductase [HMG-CoA reductase] inhibitors) are first-line agents in achieving lipid goals as an adjunct to diet and exercise and should be used in most patients. In addition to lipid management and blood pressure control, glycemic control is a basic component in the management of diabetes. Glycemic control is achieved by combining diabetes self-management education, diet and exercise, and, where required, antihyperglycemic agents (OHAs). Persistence and adherence to therapy are critical in achieving recommended treatment goals. However, overall compliance with concomitantly prescribed OHAs and statins is low in patients with type 2 diabetes. Fixed-dose combination (FDC) therapies have been shown to improve adherence by reducing pill burden, the complexity of treatment regimen, and, potentially, cost. Based on the available evidence regarding the pharmacokinetics and the efficacy and safety profiles of each component drug, the sitagliptin/simvastatin FDC may provide a rational and well-tolerated approach to achieving better adherence to multiple-drug therapy and improved lipid lowering and glycemic control, with consequent reduction in cardiovascular risk, diabetic microvascular disease, and mortality in diabetic patients for whom treatment with both compounds is appropriate.

AB - The risk of death due to heart disease and stroke is up to four times higher in individuals with diabetes compared to individuals without diabetes. Most guidelines that address treatment of dyslipidemia in patients with diabetes consider diabetes a cardiovascular disease (CVD) "risk equivalent" and recommend intensive treatment of dyslipidemia for the purpose of CVD prevention. Statins (3-hydroxy 3-methylglutaryl coenzyme A reductase [HMG-CoA reductase] inhibitors) are first-line agents in achieving lipid goals as an adjunct to diet and exercise and should be used in most patients. In addition to lipid management and blood pressure control, glycemic control is a basic component in the management of diabetes. Glycemic control is achieved by combining diabetes self-management education, diet and exercise, and, where required, antihyperglycemic agents (OHAs). Persistence and adherence to therapy are critical in achieving recommended treatment goals. However, overall compliance with concomitantly prescribed OHAs and statins is low in patients with type 2 diabetes. Fixed-dose combination (FDC) therapies have been shown to improve adherence by reducing pill burden, the complexity of treatment regimen, and, potentially, cost. Based on the available evidence regarding the pharmacokinetics and the efficacy and safety profiles of each component drug, the sitagliptin/simvastatin FDC may provide a rational and well-tolerated approach to achieving better adherence to multiple-drug therapy and improved lipid lowering and glycemic control, with consequent reduction in cardiovascular risk, diabetic microvascular disease, and mortality in diabetic patients for whom treatment with both compounds is appropriate.

UR - http://www.scopus.com/inward/record.url?scp=84891707701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891707701&partnerID=8YFLogxK

M3 - Review article

VL - 9

SP - 273

EP - 282

JO - Vascular Health and Risk Management

JF - Vascular Health and Risk Management

SN - 1176-6344

ER -